Stockwinners Market Radar for June 05, 2020 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

18:02 EDT Fang Holdings announces ADS ratio change - Fang Holdings announced that the ratio of American depositary shares representing its Class A ordinary shares is being amended from one ADS representing one Class A ordinary share to one ADS representing ten Class A ordinary shares, mainly in preparation for the pending spin-off of its internet businesses. There will be no change to Fang's Class A ordinary shares. Furthermore, no physical action by ADS holders will be required to effect the ratio change, as the change will be effected on the books of the depositary. The effect of the ratio change on the ADS trading price on New York Stock Exchange is expected to take place at the open of business on June 19 (U.S. Eastern Time). Any fractional ADSs will be sold and the net proceeds from the sale of fractional ADSs will be distributed to the holders entitled thereto. As a result of the change in the ADS ratio, the ADS price is expected to increase proportionally, although Fang can give no assurance that the ADS price after the change in the ADS ratio will be equal to or greater than ten times the ADS price before the change.

17:37 EDT General Electric awarded $180.6M Navy procurement contract - General Electric was awarded a $180.6M firm-fixed-price, indefinite-delivery/indefinite-quantity contract. This contract procures commercial depot level services for the repair and overhaul of T700-GE-401/401C turbo shaft engines, cold section modules and power turbine modules for the Navy H-60 Seahawk helicopter as well as the Marine Corps H-1 Cobra and Bell UH-1 Huey aircraft. Work will be performed in Wingsfield, Kansas and is expected to be complete by June 2025. No funds will be obligated at the time of award. Funds will be obligated on individual orders as they are issued. This contract was not competitively procured pursuant to 10 U.S. Code 2304. The Naval Air Warfare Center Aircraft Division is the contracting activity.

17:14 EDT SCWorx receives notification of deficiency from Nasdaq - SCWorx announced that on June 1 and June 2, 2020, the Nasdaq Stock Market notified the company that it was not in compliance with the Nasdaq's rules for continued listing because the company has not yet filed its 10-K for the fiscal year ended December 31, 2019, as required by Nasdaq Rule 5250(c)(1). The Nasdaq notification requires the company to submit its plan to regain compliance, no later than July 3, 2020. In response to the Nasdaq notification, the company intends to file its 2019 10-K during the week ended June 12, 2020, but in any case, before the due date for submitting its compliance plan to Nasdaq, the effect of which will be that the company will have cured the deficiency specified in the notification.

17:05 EDT TuanChe names Chenxi Yu as deputy CFO - TuanChe Limited announced that the company's board has appointed Mr. Chenxi Yu, the company's current financial controller, to serve as the deputy CFO in charge of corporate finance and financial reporting of the company, effective June 15, 2020. Mr. Yu's appointment follows the resignation of Mr. Troy Mao, the company's current chief financial officer, which will become effective on June 15, 2020. Mr. Mao and Mr. Yu will work together to ensure an orderly transition of duties. Mr. Mao resigned from his current position at the company for "personal reasons, which did not result from any disagreement with the company on any matters relating to the Company's business performance, financial reporting or controls, where the company has built a strong finance function", the company states.

16:50 EDT CACI CEO sells over 5,000 common shares - In a regulatory filing, CACI president and CEO John S. Mengucci disclosed the sale of 5,308 common shares of the company on June 4 at a price of $263.27 per share.

16:45 EDT Allegiant Travel CEO sells 165K shares of common stock - In a regulatory filing, Allegiant Travel disclosed that its CEO Maurice Gallagher sold 165K shares of common stock on June 3-4th in a total transaction size of $20.6M.

16:36 EDT ValueAct reports 7.5% stake in Enviva Partners, says shares undervalued - In a regulatory filing, ValueAct disclosed a 7.5% stake in Enviva Partners, representing 2.53M shares. The firm said it acquired the securities of the company based on the belief that the securities were undervalued and represented an attractive investment opportunity. ValueAct added that it has had and anticipates having further discussions with officers and directors of the company's general partner, in connection with ValueAct's investment in the Enviva. The topics of these conversations have covered or may cover a range of issues, including those relating to the business of the Issuer, management, board composition, investor communications, operations, capital allocation, dividend policy, financial condition, mergers and acquisitions strategy, overall business strategy, executive compensation, and corporate governance.

16:33 EDT TopBuild CEO sells 50,000 common shares - In a regulatory filing, TopBuild CEO Gerald Volas disclosed the sale of 50,000 common shares of the company on June 3 at a price of $125.087 per share.

16:31 EDT GAIN Capital stockholders approver merger with INTL FCStone - GAIN Capital Holdings announced that at a special meeting of its stockholders held earlier today, the company's stockholders voted to approve the adoption of the previously announced Agreement and Plan of Merger, dated as of February 26, 2020, by and among the Company, INTL FCStone Inc., a Delaware corporation and Golf Merger Sub I Inc., a Delaware corporation and wholly owned subsidiary of INTL, providing for the merger of Merger Sub with and into GAIN, with GAIN surviving the merger as a wholly owned subsidiary of INTL. Approximately 83.2 percent of the company's shares issued and outstanding as of the close of business on April 23, 2020, the record date for the special meeting, were present in person or by proxy at the meeting. Holders of approximately 71.2 percent of the company's shares issued and outstanding as of the close of business on the record date voted in favor of the proposal to adopt the Merger Agreement, representing approximately 85.7 percent of votes cast, excluding abstentions. Also at the special meeting, the Company's stockholders approved, by a non-binding, advisory basis, certain compensation that will or may be paid by GAIN to its named executive officers that is based on or otherwise relates to the merger. The company anticipates that the merger will be completed during the third quarter of 2020, subject to the satisfaction or waiver of the remaining customary conditions to closing, including among other things, receipt of other required regulatory approvals.

16:18 EDT AgeX Therapeutics receives noncompliance notification from NYSE - AgeX Therapeutics announced that on AgeX received a deficiency letter from the staff of the NYSE indicating that AgeX does not meet certain of the exchange's continued listing standards as set forth in Section 1003 of the exchange company guide in that AgeX has stockholders equity of less than $2M and has incurred losses from continuing operations and/or net losses during its two most recent fiscal years. Pursuant to Section 1009 of the exchange company guide and as provided in the deficiency letter AgeX intends to provide the exchange staff with a plan by July 1 advising the exchange staff of action AgeX has taken and will take that would bring AgeX into compliance with the Exchange's continued listing standards by December 1, 2021. There is no assurance that the exchange staff will accept AgeX's plan. If the exchange staff accepts AgeX's plan, the exchange staff will review AgeX's compliance with the plan on a quarterly basis and if AgeX does not show progress consistent with the plan or is not in compliance with the exchange's continued listing standards by December 1, 2021, the exchange will commence delisting procedures. If the exchange staff does not accept AgeX's plan, the exchange staff will promptly initiate delisting proceedings. AgeX intends to make arrangements to have its common stock quoted on the OTC Bulletin Board if its common stock is delisted from the NYSE American.

16:13 EDT 1st Source names Andrea Short president, Jim Seitz vice chairman - 1st Source Bank announced the Board of Directors' election of Jim Seitz as the Vice Chairman of the 1st Source Bank Board of Directors and the election of Ms. Andrea Short to President of 1st Source Bank. Short replaces Jim Seitz as president starting July 1, 2020. Seitz was elected President of 1st Source Bank in 2012, and President of 1st Source Corporation in 2014. Short was elected Chief Financial Officer of 1st Source Bank in 2013, and will continue in this capacity.

16:10 EDT TPG Specialty Lending to change name to Sixth Street Specialty Lending - TPG Specialty Lending announced that it will change its name to Sixth Street Specialty Lending, effective June 15. The new name reflects the previously announced completion of an agreement between Sixth Street Partners and TPG to become independent, unaffiliated businesses. Sixth Street is a global investment business with approximately $34B in assets under management and more than 275 team members including over 140 investment professionals globally. Sixth Street is the parent of the company's adviser, which also recently renamed from TSL Advisers to Sixth Street Specialty Lending Advisers. The company's common stock will continue to trade under the same ticker on the New York Stock Exchange.

16:06 EDT Check-Cap receives Nasdaq minimum bid price notification - Check-Cap announced that the company received a letter from the Nasdaq Listing Qualifications, indicating that the company is not in compliance with the minimum bid price requirement for continued listing set forth in Listing Rule 5550a2, which requires listed securities to maintain a minimum bid price of $1.00 per share. Further, on April 16, 2020, in response to the COVID-19 pandemic, and the resulting related market conditions, Nasdaq has elected to provide temporary relief from the bid price requirements by tolling compliance through June 30, 2020. As a result of the tolling of the bid price requirements, according to the Letter, the company has 180 calendar days from July 1, 2020, or until December 28, 2020, to regain compliance with the minimum bid price requirement. The company can regain compliance, if at any time during this 180 day period, the closing bid price of its ordinary shares is at least $1 for a minimum of ten consecutive business days, in which case the company will be provided with a written confirmation of compliance and this matter will be closed. The company may then be eligible for an additional 180 day grace period if it meets the Nasdaq Capital Market's initial listing standards with the exception of the minimum bid price requirement.

16:03 EDT RBC Bearings' Crowell sells 5,000 common shares - In a regulatory filing, RBC Bearings director Richard R. Crowell disclosed the sale of 5,000 common shares of the company on June 3 at a price of $141.298 per share.

15:34 EDT Liquidia to 'vigorously defend' against United Therapeutics patent suit - Liquidia Technologies (LQDA) announced that United Therapeutics (UTHR) filed a patent infringement action under the Hatch-Waxman Act against the company in the U.S. District Court for the District of Delaware asserting infringement of U.S. Patent Nos. 9,604,901 and 9,593,066 relating to UTC's Tyvaso, a nebulized treprostinil solution for the treatment of pulmonary arterial hypertension, or PAH. This lawsuit is in response to the New Drug Application the company filed with the U.S. Food and Drug Administration requesting approval to market LIQ861, a dry powder inhalation of treprostinil for the treatment of PAH. The LIQ861 NDA was filed under the 505(b)(2) regulatory pathway with Tyvaso as the reference listed drug. Under the Hatch-Waxman Act, the FDA is automatically precluded from approving the LIQ861 NDA for up to 30 months or until resolution of the lawsuit, absent an earlier judgment unfavorable to UTC by the court. "We believe these patents to be invalid and/or not infringed by the practice of LIQ861 and we will vigorously defend the suit and our freedom to pursue the commercialization of LIQ861. We are acutely aware of the need that exists among PAH patients to have access to treatments beyond those which are currently available and are dedicated to addressing that need in the most expedient way possible," stated Neal Fowler, CEO at Liquidia.

14:58 EDT DPH Holdings reports 15.6% passive stake in Blue Apron - In a regulatory filing, DPH Holdings disclosed a 15.6% stake in Blue Apron, which represents 1.52M shares. The filing does not allow for activism.

14:00 EDT Voyager Digital sees 'no material change' to account for recent trading activity - Voyager Digital issued a press release in response to a request by the Investment Industry Regulatory Organization of Canada, or "IIROC," to comment on recent trading activity of its stock. "The company announces that it is not aware of any material, undisclosed corporate developments and has no material change to report at this time. On May 13, 2020, the Company submitted its application to the Canadian Securities Exchange for price protection in connection with a proposed non-brokered private placement for gross proceeds of up to $3,000,000. The Canadian Securities Exchange confirmed such price protection on the same day. The company will keep the market informed as required," Voyager stated.

13:32 EDT PG&E trading resumes

13:20 EDT GrubHub jumps 7% to $61.30 after CNBC says two more suitors interested

13:03 EDT Baker Hughes reports U.S. rig count down 17 to 284 rigs - Baker Hughes reports that the U.S. rig count is down 17 rigs from last week to 284 with oil rigs down 16 to 206, gas rigs down 1 to 76, and miscellaneous rigs unchanged at 2. The U.S. Rig Count is down 691 rigs from last year's count of 975, with oil rigs down 583, gas rigs down 110, and miscellaneous rigs up 2 to 2. The U.S. Offshore Rig Count is up 1 to 13 and down 10 year-over-year. The Canada Rig Count is up 1 rig from last week to 21, with oil rigs unchanged at 7 and gas rigs up 1 to 14. The Canada Rig Count is down 82 rigs from last year's count of 103, with oil rigs down 52 and gas rigs down 30.

12:45 EDT Mack-Cali Realty modifies slate of director nominees in response to feedback - Mack-Cali Realty announced that based on the guidance of shareholders, the company has modified its slate of candidates standing for election to the Board of Directors at the company's Annual Meeting of Stockholders, scheduled for June 10. The company's slate now includes eight nominees, only three of whom have previously served on the Mack-Cali Board. Additionally, each of the Mack-Cali Board's incumbent director nominees - Lisa Myers, Laura Pomerantz and Rebecca Robertson - was elected in the last four years. The company's CEO, Michael J. DeMarco, Alan S. Bernikow, and Dr. Irvin D. Reid, each of whom is an incumbent Mack-Cali director, will not seek reelection at the 2020 Annual Meeting. Mr. DeMarco will remain as the company's CEO. The current Mack-Cali Board Chair, Governance Committee Chair and Audit Committee Chair are not standing for election, ensuring significant change in the Board's leadership."Mack-Cali is open-minded and responsive to feedback, and this new slate is reflective of shareholders' desire for continued and accelerated Board refreshment," said Lisa Myers, Independent Director of the Mack-Cali Board, on behalf of the Board. "We believe that shareholders wanted confidence that the Board would comprise fresh faces and be fully independent of management and our revised slate reflects the feedback we have heard. Our shareholders have also highlighted the importance of preserving the independence of the Board, preventing a change of control, and allowing for new perspectives while maintaining important continuity of experience. We are focused on ensuring that the Board includes truly independent directors who are committed to advancing the interests of all shareholders, so that the Company can continue to successfully execute its strategy to maximize value for all investors." Mack-Cali's slate of eight candidates includes five new nominees with experience in the public REIT space, and public company experience from across various industries. All of Mack-Cali's eight nominees are independent of the company's management, directors and the Mack family.

11:18 EDT Kroger, Ocado expand partnership with customer fulfillment centers - The Kroger Family of Companies and Ocado announced the continued expansion of their partnership with plans to construct three new Customer Fulfillment Centers in the Great Lakes, Pacific Northwest and West regions. Kroger has partnered with Ocado to accelerate its ability to provide customers with anything, anytime, anywhere. The CFC model - incorporating state-of-the-art automation and AI - will be used to expand Kroger products to a larger footprint. The new facility in the West will measure 300,000 square feet, the new facility in the Pacific Northwest will measure 200,000 square feet, and the facility in the Great Lakes region will measure 150,000 square feet. The varying sizes demonstrate the flexibility of the Ocado fulfillment ecosystem to best serve the respective markets. When operational, the facilities will collectively create more than 1,000 new jobs, with the potential for hundreds of additional career opportunities. The exact locations of the new facilities will soon be announced. The newly named locations will complement the retailer's previously announced CFC sites in Monroe, OH; Groveland, FL; Fredericksburg, MD; Atlanta, GA; Dallas, TX; and Pleasant Prairie, WI. Kroger plans to open the country's first CFC in Monroe, OH, a suburb of Cincinnati, in early 2021.

11:01 EDT Target commits $10M, ongoing resources for advancing social justice - Target announced a $10M commitment in addition to ongoing resources to advance social justice and support rebuilding and recovery efforts in local communities. "Target stands with black families, communities and team members. As we face an inflection point in Minneapolis and across the country, we're listening to our team, guests and communities, committed to using our size, scale and resources to help heal and create lasting change," said Brian Cornell, chairman and CEO, Target. Initial efforts include: A $10M investment from Target and the Target Foundation to support long-standing partners such as the National Urban League and the African American Leadership Forum in addition to adding new partners in Minneapolis-St. Paul and across the country. 10,000 hours of pro-bono consulting services for black- and people-of-color-owned small businesses in the Twin Cities, helping with rebuilding efforts. Continuing to provide essentials such as baby formula, diapers, medicine and more to communities most in need. Target Circle, the company's loyalty program, will offer guests the option to direct Target funds to local nonprofits and include organizations supporting social justice. In addition, Target has established an internal task force comprised of senior leaders from across the company. This task force will partner with Target's team members, guests and members of the community to chart the company's path forward and determine its next steps.

10:32 EDT Century Casinos reopens Mountaineer Casino, Racetrack and Resort - Century Casinos announced that operations at its Mountaineer Casino, Racetrack and Resort resumed on June 5, 2020. Thoroughbred horse racing at Mountaineer's renowned racetrack already resumed on May 31, 2020 with record breaking betting handle. Mountaineer has also reopened its popular hotel along with the casino and F&B offerings on June 5, 2020. Prior to reopening, Mountaineer implemented comprehensive and state-specific safety and social distancing protocols as directed by the West Virginia Lottery.

10:22 EDT Genius Brands names Margaret Loesch as Executive Chairman of Kartoon Channel - Genius Brands released a letter to shareholders from Chairman and CEO Andy Heyward, which states in part: "In these unprecedented times where we are all looking for healing and positivity, there is nothing more important than a smile, and that smile is the core of our product at Genius Brands...To that end, I am proud to share that this morning we announced the engagement of the most successful programming executive in the history of children's television, Margaret Loesch, as Executive Chairman of Kartoon Channel! Loesch was the founding president and CEO of Fox Kids Networks Worldwide, growing the channels across all metrics, where it was eventually sold to the Walt Disney Company for $5.5 billion. Joining Margaret will be the former President of Walt Disney Television, David Neuman, who will become Kartoon Channel!, Chief Content Officer. David, among other things, oversaw the Wonderful World of Disney and the then #1 sitcom on television, Home Improvement, and earned over 100 Emmys on his watch, while there and previously as Head of Comedy Development at NBC. It would be impossible for me to adequately sing their praises and the impact these two extraordinarily talented and accomplished people can bring to bear upon Kartoon Channel!, our new kids program service."

10:00 EDT Direxion Financial Bear 3x falls -11.2% - Direxion Financial Bear 3x is down -11.2%, or -$1.83 to $14.54.

10:00 EDT Slack Technologies falls -18.5% - Slack Technologies is down -18.5%, or -$7.02 to $30.92.

10:00 EDT SEACOR Marine Holdings rises 35.7% - SEACOR Marine Holdings is up 35.7%, or 88c to $3.33.

09:47 EDT Small Cap Bear 3x falls -12.5% - Small Cap Bear 3x is down -12.5%, or -$2.82 to $19.73.

09:47 EDT Slack Technologies falls -17.6% - Slack Technologies is down -17.6%, or -$6.68 to $31.26.

09:47 EDT Western Asset Mortgage rises 32.7% - Western Asset Mortgage is up 32.7%, or 84c to $3.41.

09:43 EDT Abiomed receives FDA approval for first-in-human trial of Impella ECP - Abiomed announces the United States Food and Drug Administration has approved the company's investigational device exemption application to start an early feasibility study with a first-in-human trial of the 9 French Impella ECP heart pump. Impella ECP, which stands for expandable cardiac power, will be studied in high-risk percutaneous coronary intervention patients. The prospective, multi-center, non-randomized early feasibility study will allow Abiomed, the study investigators, and the FDA to make qualitative assessments about the safety and feasibility of Impella ECP use in high-risk patients. The primary endpoint of the study is successful delivery, initiation and maintenance of adequate hemodynamic support and a composite rate of major device-related adverse events during high-risk PCI. The study protocol will enroll and treat up to five U.S. patients who require revascularization. If successful, enrollment will be expanded to additional patients, pending FDA approval. Study investigators will begin patient enrollment later this calendar year for the first-in-human trial. Impella ECP is available for investigational use only and is not approved for use outside of clinical studies.

09:36 EDT Resideo Technologies trading resumes

09:35 EDT Sorrento: COVIDTRAP demonstrates ability to inhibit SARS-CoV-2 in vitro - Sorrento Therapeutics announced it has completed a preclinical batch of the STI-4398 protein and is reporting the results from preclinical testing of its ability to neutralize and inhibit SARS-CoV-2 virus from infecting ACE2-expressing cells, VERO/E6. Sorrento previously announced on May 15, 2020 that it had identified a neutralizing antibody, STI-1499, that demonstrated 100% inhibition of SARS-CoV-2 virus infection in an in vitro infection experiment at a low concentration. Sorrento believes STI-1499 could be a potent antidote for COVID-19 pending successful demonstration of its safety and efficacy in pre-clinical and clinical studies. Consistent with the ambition outlined above in searching for and developing potential COVID-19 antidotes, Sorrento previously announced on March 20, 2020 that it had designed and produced its STI-4398 product candidate, a proprietary ACE2-Fc fusion protein, as a binding protein to the spike protein of the SARS-Cov-2 virus. The goal of STI-4398 is to produce a soluble SARS-CoV-2 virus-binding decoy receptor protein that binds to the spike protein and blocks the interaction of the spike protein of the SARS-CoV-2 virus with the ACE2 receptors present on the target respiratory epithelial cells. Sorrento is now reporting that in an in vitro assay, STI-4398 completely inhibited the ability of SARS-CoV-2 virus to infect VERO/E6 cells at a low concentration. Sorrento has discussed with the Food and Drug Administration the development of this drug candidate and has received guidance on the path forward to a clinical trial for STI-4398, COVIDTRAP, for both the potential treatment of infected patients and as a potential prophylactic treatment to COVID-19.

09:31 EDT Resideo Technologies trading halted, volatility trading pause

09:16 EDT ViralClear adds St. David's HealthCare to planned Phase II trial of merimepodib - BioSig Technologies and its majority owned subsidiary, ViralClear Pharmaceuticals, announced that it has expanded its patient enrollment centers to include St. David's South Austin Medical Center in Austin. The hospital is part of St. David's HealthCare, one of the largest healthcare systems in Texas. The Company intends to commence its Phase II clinical trial for merimepodib, its broad-spectrum oral anti-viral candidate for the treatment of COVID-19 in adult patients in the coming weeks. The clinical trial team consists of Brian Metzger, M.D., MPH, Medical Director of Infectious Diseases at St. David's Medical Center, who is is the principal investigator, as well as Andrea Natale, M.D., F.H.R.S., F.A.C.C., F.E.S.C., Cardiac Electrophysiologist and Executive Medical Director of the Texas Cardiac Arrhythmia Institute at St. David's Medical Center, and Matthew Robinson, M.D., Medical Director of Infectious Diseases at St. David's South Austin Medical Center, who are co-investigators for the study. The Phase II randomized, double-blind, placebo-controlled study is designed to enroll adult patients with advanced Coronavirus Disease 2019. Preclinical in vitro laboratory studies performed by the Galveston National Laboratory at The University of Texas Medical Branch demonstrated that merimepodib, provided in combination with remdesivir, showed reduction in SARS-CoV-2 replication to undetectable levels.

09:05 EDT Donaldson announces termination of purchase offer for E&E business - Donaldson announced that it has reached a mutual agreement with Nelson Global Products to terminate Nelson's previously disclosed purchase offer for Donaldson's Exhaust and Emissions, or E&E, business. "While we are disappointed the acquisition of our E&E business by Nelson will not be completed, we remain focused on our employees, customers and suppliers," said Tod Carpenter, chairman, president and CEO. "Our E&E business is defined by an incredibly talented team, robust engineering capabilities and strong customer relationships. We remain committed to delivering quality emissions products in parallel with ongoing optimization efforts to ensure our business portfolio creates long-term value for our stakeholders." Donaldson announced Nelson's purchase offer for its Exhaust and Emissions business on February 24.

09:03 EDT Medtronic recieves CE Mark for one-month DAPT indication for Resolute Onyx DES - Medtronic announced it has received CE Mark for a one-month dual antiplatelet therapy indication for high bleeding risk (HBR) patients implanted with the Resolute Onyx Drug-Eluting Stent. For HBR patients, whose bleeding risk may be increased by taking longer DAPT regimens, this new, first-of-its-kind indication allows physicians to recommend a shorter, one-month regimen of DAPT, following a percutaneous coronary intervention with Resolute Onyx. The approval is the first of its kind globally. Resolute Onyx DES is available for use in the United States, as well as in Europe and other countries that recognize the CE Mark. Resolute Onyx DES is not currently indicated for HBR patients with one-month DAPT in the United States. Data have been submitted to the FDA with the intent of obtaining a one-month DAPT US Indication for Resolute Onyx DES. The indication is based on results from the Onyx ONE Global Study, the first prospective, randomized, one-month DAPT trial comparing Resolute Onyx to a competitive DES in nearly 2,000 HBR patients. In the study, Resolute Onyx met its primary composite endpoint of cardiac death, myocardial infarction or stent thrombosis at one-year showing non-inferiority versus BioFreedom DCS. Results from the global study were shared during a Late-Breaking Clinical Trial session at the 31st Transcatheter Cardiovascular Therapeutics Conference in September 2019 and were also published in the New England Journal of Medicine. The Onyx ONE Global Study, together with the Onyx ONE Clear Study, a study that evaluated Resolute Onyx DES in HBR patients with one-month DAPT in the United States and Japan, make up the robust Medtronic Onyx ONE Month DAPT Program that has enrolled approximately 2,700 patients at up to 130 sites worldwide. To date, more than 22,000 patients have been studied in Medtronic sponsored and funded clinical trials that have addressed DAPT duration.

08:55 EDT Gol Linhas announces preliminary traffic figures for May - In the domestic market in May, demand was up by 5.0% over April and supply increased by 12.1% in relation to the previous month. GOL's domestic load factor was 74.8% in May. GOL did not operate regular international flights during the month.

08:42 EDT Avenue Therapeutics announces publications in peer-reviewed journals - Avenue Therapeutics announced the following publications in peer-reviewed journals. The publication titled "Intravenous Tramadol is Effective in the Management of Postoperative Pain Following Abdominoplasty: A Three-Arm Randomized Placebo- and Active-Controlled Trial" has been published in Drugs in R&D. The objective of this Phase 3 study was to evaluate the safety, tolerability and efficacy of IV tramadol 50 mg versus placebo in patients following abdominoplasty surgery, a soft-tissue surgical model. The study included an active comparator arm, IV morphine 4mg. While the study was not powered to provide statistical comparison of the two active arms, its sample size allowed for assessment of the general comparability of the treatment regimens. The results of the study demonstrated that IV tramadol was statistically superior to placebo and comparable to IV morphine for the primary and all key secondary efficacy outcomes. IV tramadol also demonstrated numerically lower rates of incidence of the most common treatment-emergent adverse events than IV morphine. The publication titled "IV Tramadol - A New Treatment Option for Management of Post-Operative Pain in the U.S.: An Open-Label, Single-Arm, Safety Trial Including Various Types of Surgery" has been published in Journal of Pain Research. This safety study was a Phase 3, single-arm, open-label safety study performed in patients undergoing a variety of elective bone and soft tissue surgeries to evaluate the safety and tolerability of IV tramadol 50 mg. The study enrolled 251 patients with both orthopedic and soft tissue surgeries well represented. Dosing was completed in 95% of the patients. IV tramadol was well tolerated, and the adverse events were consistent with known tramadol pharmacology. At the end of treatment, approximately 95% of the patients reported that study medication was good, very good, or excellent for controlling pain. The publication titled "Misuse of Tramadol in the United States: An Analysis of the National Survey of Drug Use and Health 2002-2017" has been published in Substance Abuse: Research and Treatment. The objective of the study was to analyze the rates of misuse - use in any way not directed by a doctor - of products containing oral tramadol, a Schedule IV opioid, as compared to comparator Schedule II opioids and alprazolam, a commonly prescribed Schedule IV controlled substance in the U.S. from the National Survey of Drug Use and Health. NSDUH is an annual, congressionally mandated household survey of self-reported alcohol, drug and tobacco use among non-institutionalized persons in the U.S. The study showed a low prevalence of oral tramadol misuse as compared to other commonly prescribed opioids when adjusted for prescription volume. Estimates of reported oral tramadol misuse remained relatively stable over time. Reports of oral tramadol misuse were also much less than alprazolam, another Schedule IV drug.

08:40 EDT Magenta Therapeutics presents preclinical CD45-ADC data at EULAR meeting - Magenta Therapeutics reported the presentation of preclinical data showing immune reset with a single dose of its CD45-ADC in models of three autoimmune diseases. Magenta also highlighted data from its Phase 1 study of first-line stem cell mobilization therapy MGTA-145. These results were presented this week at the European League Against Rheumatism, or EULAR, annual meeting. Current standard treatment for patients with multiple sclerosis involves years of chronic dosing of medications that do not halt the progression of the disease and have significant side effects. For patients with systemic sclerosis, a potentially fatal disease, there are no approved therapies. Immune reset through stem cell transplant has demonstrated remissions in thousands of patients with autoimmune diseases such as multiple sclerosis and systemic sclerosis, and it is recommended by EULAR in treatment guidelines for systemic sclerosis. A pair of comprehensive reviews published in 2017 in Nature journals summarized the clinical transplant results in multiple sclerosis and broader rheumatic autoimmune diseases. The main conclusions from this combined experience in more than 3,000 patients during the past 20 years were that the therapeutic benefit of stem cell transplant is significant across multiple trials in severe autoimmune diseases: Relapsing remitting multiple sclerosis, or RRMS, and systemic sclerosis have the most clinical evidence using stringent disease endpoints. The process for immune reset through transplant involves two main steps: removing the disease-causing cells and replacing them with healthy cells to rebuild the immune system to a healthy state. Results showed that a single dose of CD45-ADC removed disease-causing reactive T cells, enabled successful immune reset and rebuild of the immune system and was well tolerated in a reliable murine model of autoimmune disease, the EAE model. Further, a single dose of CD45-ADC significantly reduced disease incidence and delayed disease onset in this model that has successfully provided preclinical proof of concept for many clinically validated standard-of-care therapies. Data showed that a single dose of CD45-ADC eliminated disease-causing effector cells and ameliorated disease in a humanized murine model of systemic sclerosis with skin involvement. Mice treated with CD45-ADC showed clear resolution of skin lesions and regrowth of hair, while animals treated with an isotype ADC showed no improvement. Data showed that a single dose of CD45-ADC enabled immune reset and rebuild and halted disease progression in a murine model of inflammatory arthritis. The disease-modifying effects of this well-tolerated one-time approach were equivalent to multiple doses of a neutralizing anti-TNFa antibody, which replicates a clinically validated approach to treatment of rheumatoid arthritis. Magenta has identified a lead antibody for the CD45-ADC and is progressing through IND-enabling studies in 2020.

08:37 EDT Mid-Con Energy announces redetermination of borrowing base - The Partnership also announced the spring determination of the borrowing base under its senior bank debt. The new borrowing base is set at $64 million and is a reduction from the previous borrowing base of $95 million. The reduction in the borrowing base is a result of the unprecedented downturn in the oil markets. In addition, the Partnership announced the 15th Amendment to the Credit Facility, effective as of June 1, 2020. The Amendment aims to achieve $10 million in debt reduction through the next regularly scheduled redetermination of the borrowing base on or around November 2020. In addition, the Partnership will cease capital expenditures for the remainder of 2020 and look to divest non-core assets to accelerate debt repayment.

08:35 EDT Mid-Con Energy appoints Robert Boulware, Travis Goff, Fred Reynolds to board - The Partnership announced that Robert Boulware, Travis Goff and Fred Reynolds have been elected to constitute the Board of Directors of the General Partner. Robert Boulware served as President and CEO of ING Funds Distributor. Travis Goff is President of Goff Capital, a Fort Worth, Texas-based family office. Fred N. Reynolds is the principal owner of Fred S. Reynolds & Associates, a petroleum engineering consulting firm located in Fort Worth, Texas. Departing Board members include Charles R. "Randy" Olmstead, Fred Ball Jr., JohnBrown, and Peter A. Leidel, who resigned in connection with the reported transactions. Wilkie S. Colyer, Jr., the President and CEO of Contango, the parent of the new operator of the Partnership's properties, also has resigned from the Board.

08:33 EDT Mid-Con Energy completes strategic recapitalization - Mid-Con Energy Partners (MCEP) has entered into a strategic recapitalization transaction with its preferred equity holders, providing for the conversion of all Series A and B Preferred Units into common units at an average conversion price of $3.12/unit. In connection with the recapitalization, ownership of the Partnership's general partner, Mid-Con GP, has been transferred to the Partnership, resulting in strengthened corporate governance, and a new Board of Directors has been elected by written consent of the holders of a majority of the common unitholders. The Partnership also announced today the close of the spring redetermination of the borrowing base under its senior secured revolving credit facility and an amendment of the Credit Facility. The borrowing base is now set at $64M. The Partnership also announced that Contango Resources (MCF), a subsidiary of Contango Oil & Gas Company will be the new operator of the Partnership's properties, replacing Mid-Con Energy Operating, LLC. The move is expected to generate pro-forma annual cash savings of approximately $6.5 million compared to 2019. Mid-Con an upstream production company focused on conventional assets in Oklahoma and Wyoming, today announced that it has completed a strategic recapitalization transaction, resulting in significant changes to its capital structure and governance to strengthen its balance sheet, create alignment across all unit holders, reduce costs and streamline operations, thereby creating immediate and sustainable value for all unit holders. The holders of all of the Partnership's Class A and B preferred units, led by Goff Capital have agreed to convert their Preferred Units to common units at an average conversion price of $3.12/unit. In addition, the equity holders of the General Partner have agreed to contribute the ownership of the General Partner to the Partnership in exchange for common units. In connection with these transactions, the limited partnership agreement of the Partnership has been amended, the directors of the General Partner have resigned, and a new Board of Directors has been elected by written consent of affiliates of Goff Capital that now hold a majority of the outstanding common units. Following these transactions, the Partnership will have 14,311,522 common units outstanding.

08:31 EDT Ideanomics enters 50/50 JV with BBD to establish investment company - Ideanomics is pleased to announce that it has entered into a 50/50 joint venture with Business Big Data PTE, Ltd./Seasail Ventures to create an investment company focused on new infrastructure projects in China. The investment company will develop an AI-enhanced China New Infrastructure bond product, introduce capital, and fund advisory. The investment company will utilize BBD's leading AI intelligence technology to provide risk management and selection models for equity and fixed-income products. Its bond product will be the first fund of its kind that enables investors to access value in China's new infrastructure growth. The seven key development areas for new infrastructure construction are: 5G, UHV, intercity highways and intercity rail transit, new energy vehicle charging stations, big data centers, artificial intelligence, and the industrial Internet. The joint venture company has plans to create an offshore fund that invests in Chinese bonds and equities that are focused on the New Infrastructure initiative. It will be the first of its kind to take advantage of cross border financial market opportunities and AI. This fund will capture two significant emerging trends: the application of AI in traditional financial services and China's next economic upturn.

08:29 EDT NuVasive says many hospitals have restarted elective procedures - In an investor presentation, NuVasive said the impacts trends of COVID-19 are "taking shape" but that there are still "many unknowns." The company explained, "The In the U.S. and globally, many hospitals have restarted elective procedures in a measured way; The recovery of volumes lacks uniformity and highly variable by geography; Hospitals implementing new protocols and procedures within their facilities; Hospitals resuming spine surgeries may have capacity constraints as they manage the ongoing effort against COVID-19; Patient sentiment and willingness to return to both clinic and hospital settings remains unpredictable; Uncertain how unemployment or a patient's change in coverage may impact surgery postponement or cancellation trends."

08:08 EDT Biocept to relocate corporate offices, CLIA-certified laboratory to San Diego - Biocept announces that it is relocating its corporate offices and CLIA-certified, CAP-accredited high complexity laboratory to a new location in San Diego. The move is expected to be completed by 2020 year end. The company's new 39,000-square-foot headquarters, manufacturing and lab facility will be located at 9955 Mesa Rim Road, San Diego, CA 92121.

08:03 EDT Lionsgate announces June 24 re-opening for 'vertical' theme park in China - Lionsgate announced a June 24 re-opening of its critically-acclaimed world's first "vertical" theme park in Novotown on China's Henqin Island near Hong Kong and Macau. The park features one-of-a-kind immersive attractions based on such motion picture blockbusters as The Hunger Games, The Twilight Saga, Now You See Me and more. The date coincides with China's popular "Dragon Boat" long holiday weekend celebration.

08:01 EDT Arcturus Therapeutics doses first healthy volunteer in Phase 1 study of ARCT-810 - Arcturus Therapeutics announced that it has dosed the first healthy volunteer in a Phase 1 study with ARCT-810, the Company's messenger RNA-based therapeutic candidate for Ornithine Transcarbamylase deficiency. ARCT-810 utilizes Arcturus' LUNAR lipid-mediated delivery platform to effectively deliver OTC messenger RNA to liver cells. Expression of ornithine transcarbamylase enzyme in the liver of patients with OTC deficiency has the potential to restore normal urea cycle activity, preventing neurological damage and the need for liver transplantation. The ARCT-810 program is supported by preclinical data in OTC deficiency murine models demonstrating that dosing of LUNAR-OTC results in robust ornithine transcarbamylase protein expression and activity resulting in improvements in ureagenesis and plasma ammonia, and increased survival. Worldwide development and commercialization rights to ARCT-810 are entirely held by Arcturus. The ARCT-810 Phase 1 study is a double blind, placebo-controlled, dose-escalation trial in healthy adult volunteers. The study will evaluate five cohorts, each with six subjects. In each cohort, four subjects receive ARCT-810 and two receive placebo. The study will evaluate safety and tolerability, pharmacokinetics, and pharmacodynamic biomarkers.

07:32 EDT MacroGenics granted Orphan Drug designation in the U.S. for margetuximab - MacroGenics announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to margetuximab, an investigational, Fc-engineered monoclonal antibody targeting HER2 for the treatment of gastric and gastroesophageal junction cancer. Margetuximab is currently being evaluated in the Phase 2/3 MAHOGANY clinical trial in combination with checkpoint inhibition, with or without chemotherapy, as a potential first-line treatment for patients with HER2-positive gastric cancer or gastroesophageal junction cancer. The MAHOGANY study is based on results from an ongoing Phase 2 study of margetuximab plus pembrolizumab, an anti-PD-1 monoclonal antibody, for patients with advanced HER2-positive GC or GEJ cancer who have previously been treated with chemotherapy and trastuzumab in the metastatic setting. Data were presented at the European Society for Medical Oncology Annual Congress in September 2019.

07:16 EDT Aurinia Pharmaceuticals presents new subgroup analyses from AURORA trial - Aurinia Pharmaceuticals announced that new subgroup analyses from the completed AURORA pivotal trial of voclosporin were presented. The data were shared at the European League Against Rheumatism, or EULAR, 2020 E-Congress in an oral presentation. The presented data demonstrated clinically meaningful benefits of voclosporin for trial participants across ethnicities and self-reported race. Significant renal response rates were seen for Hispanic/Latino patients in the voclosporin arm versus control arm, as well as for non-Hispanic/Latino patients in the voclosporin arm versus the control arm. Furthermore, all other pre-specified subgroup analyses favored voclosporin.

07:11 EDT Acacia Research to acquire portfolio of life sciences assets for GBP 223.9M - Acacia Research announced that it had entered into an agreement with Link Fund Solutions Limited, or LFS, to purchase shares in up to 19 public and private life sciences companies from LF Equity Income Fund for a total consideration of up to GBP 223.9 million. Acacia said in a release, "The acquisition of the private companies is subject to the waiver or completion of customary pre-emption processes of such companies. The transaction will be financed with $35 million in cash currently in escrow; the issuance of $115 million in new Starboard Notes; and cash on hand. Given the unique nature of this transaction, we have amended our agreement with Starboard to allow the Company to reduce its dividend and interest expense to the extent that the full proceeds of the financing are not needed in the near term, while maintaining the ability to deploy the full $400 million in Starboard capital into new investments."

07:06 EDT Cardinal Resources debt purchase by Ghana Infrastructure Investment Fund - Cardinal Resources announcef that the senior secured credit facility has been assigned from Sprott Private Resource Lending to the Ghana Infrastructure Investment Fund, a Ghana Government owned infrastructure investment vehicle. The Company has been informed that completion of the acquisition by GIIF occurred on 4 June 2020. As a result of the acquisition, Cardinal's senior debt facility provider is now GIIF. The balance of the Facility is approximately $23.8M and Cardinal has also been provided with further funding totaling an additional $3.1M which now forms part of Cardinal's working capital. As part of the transaction, Cardinal has agreed to amend and restate the Facility under Ghanaian law. A Feasibility Study released in Q4 -2019 demonstrated that Cardinal's flagship Namdini Gold Project in Ghana's Northern District has the potential to be a low capital cost, high-margin development opportunity at a $1,350 per ounce gold price. The material commercial terms of the Facility remain unchanged or are otherwise more favourable for Cardinal, as set out below: 24-month repayment term; Interest rate of 7.75% + the greater of 3 months LIBOR or 1% per annum; Early repayment flexibility is continued and as per the arrangements with Sprott, a 5% redemption premium applies to all future repayments of the Facility; Secured against the assets of Cardinal and its wholly owned subsidiaries in Ghana; Upon a change of control of Cardinal, GIIF may require repayment of the Facility. Please refer to the Company's announcements of 16 March 2020 and 30 March 2020 in relation to the approach from Nord Gold. The Company continues to work with the Special Purpose Committee and its advisors, Maxit Capital, Hartleys Limited, BMO Capital Markets and Cannacord Genuity, to review all strategic alternatives.

07:01 EDT Sierra Metals restarts operations in Peru - Sierra Metals announces that the Peruvian Government has activated phase two of its economic recovery plan effective June 5. Phase two includes mining and mining-related activities in Peru. The company will begin to recall required furloughed employees and contractors and will start to progressively ramp the mine operations back up to full capacity. In Mexico, the Government deemed mining an essential service effective June 1, as previously discussed in the May 25 press release. The company has recalled employees from the Bolivar Mines to enter a COVID-19 screening process, allowing the company to control the risk of new infections and contamination at the mine. The Cusi Mine remains in care and maintenance for the time being, and management continues to evaluate the best path forward to complete needed development and to reach throughput targets.

06:55 EDT Mednax intends to sell Mednax Radiology Solutions - MEDNAX confirmed that it has been reviewing strategic alternatives for its radiology medical group, MEDNAX Radiology Solutions. Prior to the onset of the COVID-19 pandemic, MEDNAX had been in advanced discussions to divest this organization and plans to move forward with a divestiture, when market conditions are appropriate. MEDNAX intends to apply the proceeds from a sale of MEDNAX Radiology Solutions towards debt reduction. As part of the company's 2020 financial expectations that MEDNAX provided prior to the impact of the COVID-19 pandemic, MEDNAX Radiology Solutions was expected to contribute approximately $550M and $90M in revenue and Adjusted EBITDA, respectively, to the Company's operating results for the year. In accordance with GAAP accounting, operating results for MEDNAX Radiology Solutions will continue to be reported as part of MEDNAX's continuing operations at this time. MEDNAX does not intend to provide further public comments on this strategic alternatives process.

06:52 EDT Merck announces FDA approval of RECARBRIO - Merck announced that the U.S. FDA has approved a supplemental New Drug Application for RECARBRIO for the treatment of patients 18 years of age and older with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia, caused by the following susceptible Gram-negative microorganisms: Acinetobacter calcoaceticus-baumannii complex, Enterobacter cloacae, Escherichia coli, Haemophilus influenzae, Klebsiella aerogenes, Klebsiella oxytoca, Klebsiella pneumoniae, Pseudomonas aeruginosa and Serratia marcescens.

06:11 EDT Collier Creek to combine with Utz Quality Foods, list 'Utz Brands' on NYSE - Utz Quality Foods and Collier Creek Holdings announced that they have entered into a definitive agreement to combine and form Utz Brands. The companies said in a release, "Utz Brands will be a leading pure-play snack food platform in the U.S. Upon the closing of the transaction, it is expected that Utz Brands will trade under the ticker symbol "UTZ" on the New York Stock Exchange. After nearly a century as a family-owned business, this transaction will introduce Utz as a publicly listed company, with an anticipated initial enterprise value of approximately $1.56 billion or 11.6x its estimated 2021 Pro Forma Adjusted EBITDA of $134 million. Roger Deromedi, who was Chairman of Pinnacle Foods and, prior to that, as CEO of Kraft Foods, will become Chairman of Utz Brands. Utz Brands' board will be composed of a majority of independent directors under the applicable listing rules of the New York Stock Exchange. Dylan Lissette, who has served as Utz's CEO since 2013 and has worked at the Company for almost 25 years, will continue to lead the business along with the existing management team. Utz Brands will remain headquartered in Hanover, Pennsylvania. Proceeds from the transaction are expected to be used primarily to repay existing borrowings at Utz. The Rice and Lissette family, the founding family and owners of Utz, will retain more than 90% of its existing equity stake, which will represent more than 50% ownership in Utz Brands upon completion of the transaction. The transaction has been unanimously approved by the board of directors of Collier Creek, as well as the board of managers of Utz. The transaction is expected to close in the third quarter of 2020, subject to the satisfaction of customary closing conditions, including the approval of the shareholders of Collier Creek. Upon the closing of the transaction, Collier Creek will become a Delaware corporation and the name of Collier Creek will be changed to Utz Brands. The Rice and Lissette family is retaining more than 90% of its existing equity stake, which will represent more than 50% ownership in Utz Brands upon closing of the transaction. The remaining ownership will be held by the public shareholders and sponsor of Collier Creek. In connection with the transaction, Collier Creek's sponsor and directors will invest approximately $35 million alongside public investors via a private placement pursuant to the forward purchase agreements entered into concurrent with Collier Creek's initial public offering. Assuming no redemptions by the public shareholders of Collier Creek, the approximately $453 million in cash held in Collier Creek's trust account, together with the $35 million private placement, will be used to pay cash consideration to the current Utz owners, pay transaction expenses, and reduce the Company's existing indebtedness to approximately 3.1x estimated 2020 Pro Forma Adjusted EBITDA."

06:07 EDT Insulet resumes pivotal study of Omnipod, Powered by Horizon - Insulet announced it has resumed its pivotal study of Omnipod, Powered by Horizon, the company's personal smart-phone controlled automated insulin delivery system. The company paused the study, which was approximately halfway through completion, in March. Insulet expects to commercialize Omnipod, Powered by Horizon, in the U.S. in the first half of 2021, pending clearance by the FDA.

06:05 EDT AbbVie, three others to collaborate on antibody therapeutic to treat COVID-19 - AbbVie, Harbour BioMed, or HBM, Utrecht University, or UU, and Erasmus Medical Center, or EMC, announced they have entered into a collaboration to develop a novel antibody therapeutic to prevent and treat COVID-19, the pandemic respiratory disease caused by the SARS-CoV-2 virus. The focus of the collaboration is on advancing the fully human, neutralizing antibody 47D11 discovered by UU, EMC and HBM and recently reported in Nature Communications. This antibody targets the conserved domain of the spike protein of SARS-CoV-2. Under the terms of the collaboration, AbbVie will support UU, EMC and HBM through the preclinical activities, while simultaneously undertaking preparations for later stage preclinical and clinical development work. AbbVie will receive an option to exclusively license the antibody from the three parties for therapeutic clinical development and commercialization worldwide.

06:03 EDT Bombardier to slash workforce by about 2,500 employees

06:03 EDT AbbVie, UU, EMC and HBM collaborate on COVID-19 vaccine - AbbVie, Harbour BioMed, Utrecht University, and Erasmus Medical Center announced they have entered into a collaboration to develop a novel antibody therapeutic to prevent and treat COVID-19, the pandemic respiratory disease caused by the SARS-CoV-2 virus. The focus of the collaboration is on advancing the fully human, neutralizing antibody 47D11 discovered by UU, EMC and HBM and recently reported in Nature Communications. This antibody targets the conserved domain of the spike protein of SARS-CoV-2. Under the terms of the collaboration, AbbVie will support UU, EMC and HBM through the preclinical activities, while simultaneously undertaking preparations for later stage preclinical and clinical development work. AbbVie will receive an option to exclusively license the antibody from the three parties for therapeutic clinical development and commercialization worldwide.

05:55 EDT DBV Technologies says seven abstracts accepted at EAACI meeting - DBV Technologies announced last night that seven abstracts, including four late breakers, highlighting new data from the company's pre-clinical and clinical food allergy programs were accepted at the European Academy of Allergy & Clinical Immunology Digital Congress, June 6-8. The virtual oral and poster presentations will be available on the EAACI website to conference registrants starting Saturday, June 6. "The data we are presenting at this year's digital EAACI congress highlight potential applications of epicutaneous immunotherapy across patient populations as well as new insights into promising cellular pathways for biomarker identification," said Pharis Mohideen, M.D., Chief Medical Officer of DBV. "These presentations highlight the breadth of research DBV is conducting on the science and impact of food allergy as part of our commitment to improving the lives of patients through innovative potential treatments like epicutaneous immunotherapy. Our lead candidate, Viaskin Peanut, is currently under FDA review, and we look forward to making this investigational therapy available for patients as soon as possible, if approved."

05:21 EDT Caledonia Mining applies for voluntary delisting from TSX - Caledonia Mining announces that it has applied for a voluntary delisting from the Toronto Stock Exchange, or the TSX, effective as of the closing of trading on June 19. Caledonia said in a release, "Following delisting, the Company's shares will continue to be listed and trade on NYSE American under the symbol "CMCL". Depositary interests representing shares will also continue to trade on AIM of the London Stock Exchange plc under the symbol "CMCL". Since the Company's shares were listed on the NYSE American in 2017, trading on that market has become increasingly dominant, and it now provides the most liquid market for Caledonia's shares. Accordingly, the Company believes that the financial and administrative costs associated with maintaining its listing on the TSX are no longer justified. Shareholders holding shares in Canadian brokerage accounts should contact their brokers to confirm how to trade in Caledonia's shares in the future on NYSE American or through depositary interests on AIM."